Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden (Q37153047)

18 August 2017

Heterogeneity in cost-effectiveness of lifestyle counseling for metabolic syndrome risk groups -primary care patients in Sweden (English)

1 reference

cost-effectiveness analysis

18 August 2017

0 references

1 reference

1 reference

1 reference

Inna Feldman

1

1 reference

18 August 2017

Lennart Hellström

series ordinal

2

1 reference

18 August 2017

Pia Johansson

series ordinal

3

1 reference

18 August 2017

28 August 2013

1 reference

Cost Effectiveness and Resource Allocation

18 August 2017

1 reference

18 August 2017

11

1 reference

18 August 2017

19

1 reference

18 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1186/1478-7547-11-19

18 August 2017

0 references

cites work

Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Economic evaluation of lifestyle interventions for preventing diabetes and cardiovascular diseases.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

A 3-year randomized trial of lifestyle intervention for cardiovascular risk reduction in the primary care setting: the Swedish Björknäs study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Is prevention of Type-2 diabetes feasible and efficient in primary care? A systematic PubMed review

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Tuberculosis screening of travelers to higher-incidence countries: a cost-effectiveness analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Subgroup analysis and other (mis)uses of baseline data in clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Cost-utility analysis of topical intranasal steroids for otitis media with effusion based on evidence from the GNOME trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

A multinational investigation of time and traveling costs in attending anticoagulation clinics

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Modelling the lifetime costs and health effects of lifestyle intervention in the prevention and treatment of obesity in Switzerland

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Lessons from trial-based cost-effectiveness analyses of mental health interventions: why uncertainty about the outcome, estimate and willingness to pay matters.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Cost-effectiveness of screening for pre-diabetes among overweight and obese U.S. adults.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Relative cost effectiveness of the SPHERE intervention in selected patient subgroups with existing coronary heart disease

3 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1186%2F1478-7547-11-19

Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3765778

Reflecting heterogeneity in patient benefits: the role of subgroup analysis with comparative effectiveness

4 December 2018

1 reference

12 December 2020

Uncertainty in decision-making: value of additional information in the cost-effectiveness of lifestyle intervention in overweight and obese people

1 reference

12 December 2020

Targeting patients for statin therapy for the primary prevention of vascular events: what is the best approach?

1 reference

12 December 2020

Subgroups and heterogeneity in cost-effectiveness analysis

1 reference

12 December 2020

[Health economics play more and more important role in health care prioritization. Better utilization of the meager health care resources is the goal]

1 reference

12 December 2020

Identifiers

DOI

10.1186/1478-7547-11-19

1 reference

Dimensions Publication ID

18 August 2017

0 references

1 reference

18 August 2017

1 reference